We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioAlliance Announces Phase I Trial for Fentanyl Lauriad® and the Submission of a Clonidine Lauriad® Phase II Clinical Trial Application
News

BioAlliance Announces Phase I Trial for Fentanyl Lauriad® and the Submission of a Clonidine Lauriad® Phase II Clinical Trial Application

BioAlliance Announces Phase I Trial for Fentanyl Lauriad® and the Submission of a Clonidine Lauriad® Phase II Clinical Trial Application
News

BioAlliance Announces Phase I Trial for Fentanyl Lauriad® and the Submission of a Clonidine Lauriad® Phase II Clinical Trial Application

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioAlliance Announces Phase I Trial for Fentanyl Lauriad® and the Submission of a Clonidine Lauriad® Phase II Clinical Trial Application"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioAlliance Pharma SA has announced the approval from the French Drug Agency (AFSSaPS) to enter first Phase I clinical trial for Fentanyl Lauriad®.

This clinical trial will evaluate the plasma pharmacokinetic parameters of Fentanyl Lauriad® in healthy volunteers. It is expected to complete before end 2009.

Fentanyl Lauriad® is based on the proprietary muco-adhesive technology already validated with Loramyc®, BioAlliance already marketed drug, and with acyclovir Lauriad® positive Phase III clinical trial. This new sustained release product is dedicated to the treatment of cancer chronic pain.

Clonidine Lauriad®, the fourth product using the same technology, is being developed for the treatment of oral mucositis. A Phase II clinical trial application has been submitted to the French Drug Agency and the first patient should be recruited early 2010.

“BioAlliance confirms it is accelerating the development of supportive care products in oncology, such as the treatment of chronic pain and mucositis that are both frequent complications of cancer and its treatments”, added Dominique Costantini, President and CEO of BioAlliance Pharma.
Advertisement